DraftKings enters September with a sharp week-on-week decline, a fresh high-conviction initiation from a bellwether firm, and a borrow market so loose it barely registers — a combination that makes the stock's near-term tension more about the Street's conviction than about short-side pressure.
The stock fell 9.1% on the week to close at $23.44, with 3.5% of that drop coming in Tuesday's session alone. The month-to-date damage is minimal — just 0.2% — which suggests the weekly move is concentrated noise rather than a structural re-rating. Closest peer FLUT dropped 5% on the same week, and GENI fell nearly 10%, so sector-wide selling is doing some of the work. The context matters: DKNG's most recent earnings print on August 7 produced a 9.5% one-day rally and a 17.9% five-day gain — the stock can move violently in either direction around key catalysts, and the next print isn't until November 5.
Positioning tells an unusually relaxed story for a stock sitting 7.7% short of its free float. Short interest added roughly 4% on the week to 38.4 million shares — a modest rebuild after a multi-week slide that took SI from above 39 million in early August down to 36.9 million at its low. But the borrow market is anything but strained. Availability is running at 3,252% — meaning there are more than thirty shares available to borrow for every one already lent out — which is well above the 52-week low of 462%. Cost to borrow has crept up to 0.50%, its highest level in roughly six weeks and up 13% on the week, but at half a percent it remains a non-factor for short-sellers weighing the carry cost. Options traders are equally relaxed: the put/call ratio at 0.33 is fractionally below its 20-day average of 0.33, nearly flat to a z-score of -0.27, and well off its 52-week high of 0.62. Hedging demand is absent. Overall, positioning looks uncrowded on the short side and unbothered on the options side — the week's price drop is not accompanied by any visible defensive repositioning.
The Street, however, is where the week's real story sits. Wolfe Research initiated coverage on September 2 with an Outperform rating and a $40 target — the highest on the Street among the most recent cluster of analyst actions. That $40 target implies 71% upside from Tuesday's close and arrives immediately after a week where most other analysts were trimming. Following August's earnings, JPMorgan cut its target from $34 to $33 while keeping Overweight; Barclays and Guggenheim both nudged targets lower to $34 and $33 respectively; Citigroup, however, raised to $32 from $30, maintaining Buy. The consensus remains firmly constructive — 25 buys and a mean target of $35.12, roughly 50% above the current print. Bulls point to the expansion into Predictions and a $13-16 billion revenue outlook by year-end, while bears flag market-share attrition, slower-than-expected state legalisation, and the structural disadvantage of lacking retail casino infrastructure. Valuation has re-rated modestly lower: the price-to-book multiple has fallen nearly 2.9 points over the past 30 days to 10.5x, and EV/EBITDA has compressed by about 1.1 turns to 12.8x — both consistent with a stock that has drifted sideways over the month while earnings estimates edged higher. The forward EPS momentum factor ranks in the 92nd percentile, meaning earnings growth expectations are accelerating faster than almost every other name in the universe — a contrast with the near-term EPS surprise rank of just 6, which captures the recent miss.
Institutional ownership adds an interesting footnote. Three new Schedule 13G filings landed in August. CIBC (through its asset management arm) emerged as the single largest holder at roughly 7.3% of shares, filing on August 13. AQR Capital Management filed the same day at 5.98%. Kenneth Dart filed at 5.8% on August 14 — his entire 28.6 million share position is listed as a new entry. None carry 13D activist intent; all are passive disclosures. The concentration of these August filings suggests fresh institutional accumulation occurred around the stock's post-earnings lows in early August, when DKNG was still trading closer to $21 based on the SI history and the subsequent price recovery.
With the next earnings date six weeks out and the Wolfe initiation establishing a fresh upside anchor at $40, the near-term debate narrows to whether the September price weakness is an entry point for conviction buyers or a signal that competitive headwinds are more durable than the bull case allows — and the ORTEX short score, sitting flat near 46 for the past two weeks, is offering no strong steer in either direction.
See the live data behind this article on ORTEX.
Open DKNG on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
